Related Experiment Videos
Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patients
1Department of Clinical Chemistry, Ribe County Hospital, Esbjerg, Denmark.
Abstract:
Despite the fact that the relationship between impaired diabetic control and the development of vascular complications now seems less controversial than before, we are still in a situation where interventions or strategies aimed at decreasing the complications of late diabetes have high priorities. It is believed that accelerated vascular disease in the diabetic population is caused by repeated intimal injury of the arteries, and there is also evidence that the accelerated vascular disease states cannot be attributed only to the hyperglycemic state. One factor of importance for delayed tissue repair and arteriosclerotic disease in diabetic patients might be a disordered endothelial cell-dependent fibrinolytic system. Here, we review the evidence of the relationship between increased fibrin deposition and defective fibrinolysis in diabetic patients, and, furthermore, we discuss the possible beneficial effects of an enhancement of endogenous endothelial cell-related fibrinolysis by sulphonylurea drugs.
Insights
Diabetic patients show impaired fibrinolysis, increasing vascular complication risks. Enhancing this system with sulfonylurea drugs may offer protective benefits against diabetes-related vascular disease.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Hematology
Background:
- Impaired glycemic control in diabetes mellitus is linked to vascular complications.
- Accelerated vascular disease in diabetics may stem from intimal injury and factors beyond hyperglycemia.
- Disordered endothelial cell fibrinolysis may contribute to poor tissue repair and arteriosclerosis in diabetic patients.
Purpose of the Study:
- To review evidence linking increased fibrin deposition and defective fibrinolysis in diabetic patients.
- To discuss the potential benefits of sulfonylurea drugs in enhancing endothelial fibrinolysis.
Main Methods:
- Literature review of studies on diabetes, vascular complications, and fibrinolysis.
- Analysis of evidence regarding endothelial cell function and fibrinolytic pathways.
- Discussion of pharmacological interventions, specifically sulfonylureas.
Main Results:
- Diabetic patients exhibit a defective fibrinolytic system, characterized by increased fibrin deposition.
- Evidence suggests a connection between impaired fibrinolysis and the development of vascular complications in diabetes.
- Sulfonylurea drugs show potential for enhancing endogenous fibrinolysis.
Conclusions:
- Defective fibrinolysis is a significant factor in diabetic vascular complications.
- Enhancing endothelial cell-related fibrinolysis, potentially with sulfonylurea drugs, could be a therapeutic strategy for diabetic patients.